Please assess the completion status of the following clinical trial:

Trial Title: Treatment Of Chronic Anal Fissure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Danish citizens, age ≥ 18 years~2. Presence of a midline anal fissure, dorsal or ventral~3. Pain during and after defecation lasting for more than 8 weeks~4. Presence of a sentinel anal tag or hypertrophic papilla~5. Exposure of the horizontal fibres of the internal anal sphincter~1-3 has to be fulfilled for inclusion. Additionally 4 AND/OR 5 has to be present~Exclusion Criteria:~1. Inflammatory bowel disease, known venereal disease, immunodeficiency disease~2. Anal/perianal abscess~3. Anal or rectal surgery within 12 weeks~4. Pregnancy or breastfeeding females~5. History of migraine or chronic headache requiring treatment with analgetics~6. Any cardiovascular or cerebrovascular disease~7. Current use of calcium channel blockers in general or history of use of calcium channel blockers in the treatment of the fissure~8. Signs of other rectal diseases, fistula, infection including severe perianal eczema and tumours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diltiazem, calcium channel blocker (Type: ACTIVE_COMPARATOR): Diltiazem gel 2% applied twice daily for 8 weeks
- Levorag, Hibiscus plant extract (Type: EXPERIMENTAL): Levorag Emulgel applied twice daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).